Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
A$299
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
Mazdutide is a GLP-1R/GcgR dual agonist (IBI362) designed with a C18 fatty acid modification for extended half-life in pharmacokinetic research models.
The GLP-1/glucagon dual-agonist class is of particular interest in receptor pharmacology because glucagon and GLP-1 share ~50% sequence homology yet produce opposed metabolic responses in hepatocyte models. Peptides that activate both simultaneously allow dissection of whether GcgR agonism amplifies or competes with GLP-1R outputs at the cellular level.
Browse Inventory
In research literature, Mazdutide is generally treated as a GLP-1R/GcgR dual agonist (IBI362) designed with a C18 fatty acid modification for extended half-life in pharmacokinetic research models. Mazdutide activates the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GcgR) — both class B GPCRs — with differential potency ratios engineered to bias signalling toward GLP-1 pathway outputs while retaining GcgR-mediated increases in hepatic cAMP relevant to lipid oxidation assay models. This GLP-1-biased dual agonism is structurally distinct from tirzepatide (GIP/GLP-1) and retatrutide (GLP-1/GIP/GcgR), placing mazdutide in a unique position in head-to-head receptor-selectivity comparator panels.
The GLP-1/glucagon dual-agonist class is of particular interest in receptor pharmacology because glucagon and GLP-1 share ~50% sequence homology yet produce opposed metabolic responses in hepatocyte models. Peptides that activate both simultaneously allow dissection of whether GcgR agonism amplifies or competes with GLP-1R outputs at the cellular level. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Mazdutide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for Mazdutide should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for Mazdutide is:
If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare Mazdutide with Klow, BPC-157 + TB-500, and Glow, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
It brings together 2 labelled variants: 5mg and 10mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
Mazdutide is generally discussed as a GLP-1R/GcgR dual agonist (IBI362) designed with a C18 fatty acid modification for extended half-life in pharmacokinetic research models. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
This page links the broader COA library when a product-specific document is not attached. Laboratories should use the published documentation set that is currently available for the listing.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
